Dr. Reddya[euro](tm)s Laboratories unveils USFDA approved Gemcitabine for Injection.
M2 EQUITYBITES-July 28, 2011-Dr. Reddya[euro](tm)s Laboratories unveils USFDA approved Gemcitabine for Injection(C)2011 M2 COMMUNICATIONS http://www.m2.com
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the launch of Gemcitabine for Injection (200 mg/vial and 1g/vial) in the US market on 25 July 2011.
The company stated its United States Food & Drug Administration (USFDA) Gemcitabine for Injection is a bio equivalent generic version of Gemzar.
According to IMS Health, the Gemzar brand recorded US sales of approximately USD634m for the most recent 12 months ending 31 May 2011.
In addition, the company said its Gemcitabine for Injection 200mg/vial and 1 g/vial strengths are available in single-use vials.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jul 28, 2011|
|Previous Article:||Braskem SA acquires The Dow Chemical Company's USD323m Polypropylene business.|
|Next Article:||-Spain's BBVA records decline in H1 profit.|